Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Nature Genetics

Volumn 47, Issue 5, 2015, Pages 505-511

  Schulze, Kornelius ^a,b,c   Imbeaud, Sandrine ^a,b,c   Letouzé, Eric ^a,b,c   Alexandrov, Ludmil B ^d,e   Calderaro, Julien ^a,b,c,f   Rebouissou, Sandra ^a,b,c   Couchy, Gabrielle ^a,b,c   Meiller, Clément ^a,b,c   Shinde, Jayendra ^a,b,c   Soysouvanh, Frederic ^a,b,c   Calatayud, Anna Line ^a,b,c   Pinyol, Roser ^g   Pelletier, Laura ^a,b,c   Balabaud, Charles ^h   Laurent, Alexis ^a,b,c,f   Blanc, Jean Frederic ^h,i   Mazzaferro, Vincenzo ^j   Calvo, Fabien ^a,b,c   Villanueva, Augusto ^g,k   Nault, Jean Charles ^a,b,c,l   Bioulac Sage, Paulette ^h,m   Stratton, Michael R ^d   Llovet, Josep M ^g,k,n   Zucman Rossi, Jessica ^a,b,c,o   more..

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS 13   (France)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e LOS ALAMOS NATIONAL LABORATORY   (United States)

^f HENRI MONDOR HOSPITAL   (France)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITÉ DE BORDEAUX   (France)

ⁱ HÔPITAL SAINT ANDRÉ   (France)

^j NATIONAL CANCER INSTITUTE   (Italy)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^m HÔPITAL PELLEGRIN   (France)

ⁿ INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^o HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN B1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; PROTEIN P53; 17-(DIMETHYLAMINOETHYLAMINO)-17-DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; BENZOQUINONE DERIVATIVE; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; NQO1 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TANESPIMYCIN;

ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CANCER STAGING; EXOME; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOMICS; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; TOBACCO CONSUMPTION; AGED; ANTAGONISTS AND INHIBITORS; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE DELETION; GENETICS; LIVER NEOPLASMS; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; NUCLEOTIDE SEQUENCE; RISK FACTOR; TUMOR CELL LINE;

HEPATITIS B VIRUS; NICOTIANA TABACUM;

AGED; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; EXOME; FEMALE; GENETIC ASSOCIATION STUDIES; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; LIVER NEOPLASMS; MALE; MOLECULAR TARGETED THERAPY; NAD(P)H DEHYDROGENASE (QUINONE); RISK FACTORS; SEQUENCE DELETION;

EID: 84929129284     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.3252     Document Type: Article

References (40)

1. Forner, A., Llovet, J.M. & Bruix, J. Hepatocellular carcinoma. Lancet 379, 1245-1255 (2012
2. El-Serag, H.B. Hepatocellular carcinoma. N. Engl. J. Med. 365, 1118-1127 (2011
3. International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 49, 658-664 (2009
4. Roncalli, M. et al. Liver precancerous lesions and hepatocellular carcinoma: the histology report. Dig. Liver Dis. 43 (suppl. 4), S361-S372 (2011
5. Zucman-Rossi, J. et al. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43, 515-524 (2006
6. Nault, J.C., Bioulac-Sage, P. & Zucman-Rossi, J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology 144, 888-902 (2013
7. Pilati, C. et al. Genomic profiling of hepatocellular adenomas reveals recurrent FRK-Activating mutations and the mechanisms of malignant transformation. Cancer Cell 25, 428-441 (2014
8. Bruix, J., Gores, G.J. & Mazzaferro, V. Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63, 844-855 (2014
9. Llovet, J.M. & Hernandez-Gea, V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072-2079 (2014
10. French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 20, 15-20 (1994
11. Guichard, C. et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698 (2012
12. Fujimoto, A. et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat. Genet. 44, 760-764 (2012
13. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013
14. Alexandrov, L.B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013
15. Helleday, T., Eshtad, S. & Nik-Zainal, S. Mechanisms underlying mutational signatures in human cancers. Nat. Rev. Genet. 15, 585-598 (2014
16. Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Campbell, P.J. & Stratton, M.R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013
17. Alexandrov, L.B. & Stratton, M.R. Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr. Opin. Genet. Dev. 24, 52-60 (2014
18. Hsu, I.C. et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427-428 (1991
19. Bressac, B., Kew, M., Wands, J. & Ozturk, M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350, 429-431 (1991
20. Totoki, Y. et al. Trans-Ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet. 46, 1267-1273 (2014
21. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-Associated genes. Nature 499, 214-218 (2013
22. Sawey, E.T. et al. Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by oncogenomic screening. Cancer Cell 19, 347-358 (2011
23. Chiang, D.Y. et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res. 68, 6779-6788 (2008
24. Nault, J.C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013
25. Totoki, Y. et al. Unique mutation portraits and frequent COL2A1 gene alteration in chondrosarcoma. Genome Res. 24, 1411-1420 (2014
26. Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012
27. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012
28. Siegel, D. et al. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H: quinone oxidoreductase 1. Mol. Pharmacol. 59, 263-268 (2001
29. Ahn, S.M. et al. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification. Hepatology 60, 1972-1982 (2014
30. Wang, K. et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58, 706-717 (2013
31. Hyeon, J., Ahn, S., Lee, J.J., Song, D.H. & Park, C.K. Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma. Dig. Dis. Sci. 58, 1916-1922 (2013
32. Miura, S. et al. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Cancer 12, 56 (2012
33. Song, S. et al. qpure: a tool to estimate tumor cellularity from genome-wide single-nucleotide polymorphism profiles. PLoS ONE 7, e45835 (2012
34. Miller, S.A., Dykes, D.D. & Polesky, H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988
35. Gnirke, A. et al. Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing. Nat. Biotechnol. 27, 182-189 (2009
36. Adzhubei, I.A. et al. A method and server for predicting damaging missense mutations. Nat. Methods 7, 248-249 (2010
37. Waltz, R.A., Morales, J.L., Nocedal, J. & Orban, D. An interior algorithm for nonlinear optimization that combines line search and trust region steps. Math. Program. 107, 391-408 (2006
38. Olshen, A.B., Venkatraman, E.S., Lucito, R. & Wigler, M. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004
39. Troncale, S. et al. NormaCurve: a SuperCurve-based method that simultaneously quantifies and normalizes reverse phase protein array data. PLoS ONE 7, e38686 (2012
40. Hope, A.C.A. A simplified Monte Carlo significance test procedure. J. R. Stat. Soc. Ser. B 30, 582-598 (1968